231 related articles for article (PubMed ID: 23890523)
21. [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
Xu J; Xu Z; Qin T; Li B; Fang L; Zhang H; Hu N; Pan L; Qu S; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):698-702. PubMed ID: 25152115
[TBL] [Abstract][Full Text] [Related]
22. Thalidomide and lenalidomide in primary myelofibrosis.
Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
[TBL] [Abstract][Full Text] [Related]
24. Responses to pomalidomide and placebo in myelofibrosis-related anaemia.
Ross DM
Leukemia; 2017 Mar; 31(3):532-533. PubMed ID: 27932792
[No Abstract] [Full Text] [Related]
25. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Daver N; Cortes J; Newberry K; Jabbour E; Zhou L; Wang X; Pierce S; Kadia T; Sasaki K; Borthakur G; Ravandi F; Pemmaraju N; Kantarjian H; Verstovsek S
Haematologica; 2015 Aug; 100(8):1058-63. PubMed ID: 26088933
[TBL] [Abstract][Full Text] [Related]
26. Thalidomide treatment in a myelofibrosis patient with leukemia transformation.
Huang WH; Li MS; Chu SC; Wang TF; Kao RH; Wu YF
Int J Hematol; 2014 Feb; 99(2):188-92. PubMed ID: 24307514
[TBL] [Abstract][Full Text] [Related]
27. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Larocca A; Montefusco V; Bringhen S; Rossi D; Crippa C; Mina R; Galli M; Marcatti M; La Verde G; Giuliani N; Magarotto V; Guglielmelli T; Rota-Scalabrini D; Omedé P; Santagostino A; Baldi I; Carella AM; Boccadoro M; Corradini P; Palumbo A
Blood; 2013 Oct; 122(16):2799-806. PubMed ID: 23954889
[TBL] [Abstract][Full Text] [Related]
28. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
29. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
Luo X; Xu Z; Li B; Qin T; Zhang P; Zhang H; Fang L; Pan L; Hu N; Qu S; Zhang Y; Huang G; Peter Gale R; Xiao Z
Blood Cancer J; 2018 Jan; 8(1):9. PubMed ID: 29335406
[TBL] [Abstract][Full Text] [Related]
30. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.
Ellis PM; Jungnelius U; Zhang J; Fandi A; Beck R; Shepherd FA
J Thorac Oncol; 2013 Apr; 8(4):423-8. PubMed ID: 23370364
[TBL] [Abstract][Full Text] [Related]
32. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
[TBL] [Abstract][Full Text] [Related]
33. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Dimopoulos MA; Palumbo A; Corradini P; Cavo M; Delforge M; Di Raimondo F; Weisel KC; Oriol A; Hansson M; Vacca A; Blanchard MJ; Goldschmidt H; Doyen C; Kaiser M; Petrini M; Anttila P; Cafro AM; Raymakers R; San-Miguel J; de Arriba F; Knop S; Röllig C; Ocio EM; Morgan G; Miller N; Simcock M; Peluso T; Herring J; Sternas L; Zaki MH; Moreau P
Blood; 2016 Jul; 128(4):497-503. PubMed ID: 27226434
[TBL] [Abstract][Full Text] [Related]
35. Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Shah J; Usmani S; Stadtmauer EA; Rifkin RM; Berenson JR; Berdeja JG; Lyons RM; Klippel Z; Chang YL; Niesvizky R
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):570-578.e1. PubMed ID: 31326409
[TBL] [Abstract][Full Text] [Related]
36. Thalidomide in agnogenic and secondary myelofibrosis.
Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M
Br J Haematol; 2001 Nov; 115(2):313-5. PubMed ID: 11703326
[TBL] [Abstract][Full Text] [Related]
37. Two cases of myelofibrosis with severe thrombocytopenia and symptomatology successfully treated with combination of pomalidomide and ruxolitinib.
Andrei M; Sindhu H; Wang JC
Leuk Lymphoma; 2015 Feb; 56(2):524-6. PubMed ID: 24893800
[No Abstract] [Full Text] [Related]
38. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Chowdhury O; O'Sullivan J; Barkas N; Wang G; Buck G; Hamblin A; Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; Ribrag V; Schiller G; Vannucchi AM; Zhou D; McMullin MF; Zhong J; Gale RP; Mead AJ;
Leukemia; 2021 Apr; 35(4):1197-1202. PubMed ID: 32770086
[No Abstract] [Full Text] [Related]
39. Does anything work for anaemia in myelofibrosis?
Birgegård G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):175-85. PubMed ID: 25189728
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
